These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 24756971)

  • 1. Osteoprotegerin and kidney disease.
    Montañez-Barragán A; Gómez-Barrera I; Sanchez-Niño MD; Ucero AC; González-Espinoza L; Ortiz A
    J Nephrol; 2014 Dec; 27(6):607-17. PubMed ID: 24756971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular calcification in type-2 diabetes and cardiovascular disease: Integrative roles for OPG, RANKL and TRAIL.
    Harper E; Forde H; Davenport C; Rochfort KD; Smith D; Cummins PM
    Vascul Pharmacol; 2016 Jul; 82():30-40. PubMed ID: 26924459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor necrosis factor-related apoptosis-inducing ligand and vascular calcification.
    Chasseraud M; Liabeuf S; Mozar A; Mentaverri R; Brazier M; Massy ZA; Kamel S
    Ther Apher Dial; 2011 Apr; 15(2):140-6. PubMed ID: 21426505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TRAIL-deficiency accelerates vascular calcification in atherosclerosis via modulation of RANKL.
    Di Bartolo BA; Cartland SP; Harith HH; Bobryshev YV; Schoppet M; Kavurma MM
    PLoS One; 2013; 8(9):e74211. PubMed ID: 24040204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased calcification in osteoprotegerin-deficient smooth muscle cells: Dependence on receptor activator of NF-κB ligand and interleukin 6.
    Callegari A; Coons ML; Ricks JL; Rosenfeld ME; Scatena M
    J Vasc Res; 2014; 51(2):118-31. PubMed ID: 24642764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Osteoprotegerin in Vascular Calcification and Bone Metabolism: The Basis for Developing New Therapeutics.
    Rochette L; Meloux A; Rigal E; Zeller M; Malka G; Cottin Y; Vergely C
    Calcif Tissue Int; 2019 Sep; 105(3):239-251. PubMed ID: 31197415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways.
    Vitovski S; Phillips JS; Sayers J; Croucher PI
    J Biol Chem; 2007 Oct; 282(43):31601-9. PubMed ID: 17702740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No influence of OPG and its ligands, RANKL and TRAIL, on proliferation and regulation of the calcification process in primary human vascular smooth muscle cells.
    Olesen M; Skov V; Mechta M; Mumm BH; Rasmussen LM
    Mol Cell Endocrinol; 2012 Oct; 362(1-2):149-56. PubMed ID: 22698523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RANKL, but Not R-Spondins, Is Involved in Vascular Smooth Muscle Cell Calcification through LGR4 Interaction.
    Fernández-Villabrille S; Martín-Vírgala J; Martín-Carro B; Baena-Huerta F; González-García N; Gil-Peña H; Rodríguez-García M; Fernández-Gómez JM; Fernández-Martín JL; Alonso-Montes C; Naves-Díaz M; Carrillo-López N; Panizo S
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteoprotegerin and osteoprotegerin/TRAIL ratio are associated with cardiovascular dysfunction and mortality among patients with renal failure.
    Kuźniewski M; Fedak D; Dumnicka P; Stępień E; Kuśnierz-Cabala B; Cwynar M; Sułowicz W
    Adv Med Sci; 2016 Sep; 61(2):269-275. PubMed ID: 27128817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The osteoprotegerin/tumor necrosis factor related apoptosis-inducing ligand axis in the kidney.
    Candido R
    Curr Opin Nephrol Hypertens; 2014 Jan; 23(1):69-74. PubMed ID: 24247823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone marrow- or vessel wall-derived osteoprotegerin is sufficient to reduce atherosclerotic lesion size and vascular calcification.
    Callegari A; Coons ML; Ricks JL; Yang HL; Gross TS; Huber P; Rosenfeld ME; Scatena M
    Arterioscler Thromb Vasc Biol; 2013 Nov; 33(11):2491-500. PubMed ID: 23990207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibroblast growth factor 21 plays an inhibitory role in vascular calcification in vitro through OPG/RANKL system.
    Cao F; Liu X; Cao X; Wang S; Fu K; Zhao Y; Shen F; Liu J
    Biochem Biophys Res Commun; 2017 Sep; 491(3):578-586. PubMed ID: 28774557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcium and osteoprotegerin regulate IGF1R expression to inhibit vascular calcification.
    Di Bartolo BA; Schoppet M; Mattar MZ; Rachner TD; Shanahan CM; Kavurma MM
    Cardiovasc Res; 2011 Aug; 91(3):537-45. PubMed ID: 21447702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The receptor activator of nuclear factor κΒ ligand receptor leucine-rich repeat-containing G-protein-coupled receptor 4 contributes to parathyroid hormone-induced vascular calcification.
    Carrillo-López N; Martínez-Arias L; Alonso-Montes C; Martín-Carro B; Martín-Vírgala J; Ruiz-Ortega M; Fernández-Martín JL; Dusso AS; Rodriguez-García M; Naves-Díaz M; Cannata-Andía JB; Panizo S
    Nephrol Dial Transplant; 2021 Mar; 36(4):618-631. PubMed ID: 33367746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours.
    Van Poznak C; Cross SS; Saggese M; Hudis C; Panageas KS; Norton L; Coleman RE; Holen I
    J Clin Pathol; 2006 Jan; 59(1):56-63. PubMed ID: 16394281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRAIL, OPG, and TWEAK in kidney disease: biomarkers or therapeutic targets?
    Bernardi S; Voltan R; Rimondi E; Melloni E; Milani D; Cervellati C; Gemmati D; Celeghini C; Secchiero P; Zauli G; Tisato V
    Clin Sci (Lond); 2019 May; 133(10):1145-1166. PubMed ID: 31097613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Osteoprotegerin and Its Ligands in Vascular Function.
    Rochette L; Meloux A; Rigal E; Zeller M; Cottin Y; Vergely C
    Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30736365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated serum osteoprotegerin levels in women: friend or foe?
    Sasso GR; Florencio-Silva R; Simões RS; Baracat MC; Soares Júnior JM; Baracat EC
    Rev Assoc Med Bras (1992); 2015; 61(6):524-9. PubMed ID: 26841162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo.
    Zinonos I; Labrinidis A; Lee M; Liapis V; Hay S; Ponomarev V; Diamond P; Findlay DM; Zannettino AC; Evdokiou A
    J Bone Miner Res; 2011 Mar; 26(3):630-43. PubMed ID: 20818644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.